These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 30301525

  • 1. Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling.
    Li Y, Hu J, Song H, Wu T.
    Biochem Biophys Res Commun; 2018 Nov 02; 505(3):858-864. PubMed ID: 30301525
    [Abstract] [Full Text] [Related]

  • 2. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
    Zhou Z, Liu T, Zhang J.
    Biochem Biophys Res Commun; 2019 Dec 10; 520(3):560-565. PubMed ID: 31615652
    [Abstract] [Full Text] [Related]

  • 3. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H.
    Biomed Pharmacother; 2020 Sep 10; 129():110390. PubMed ID: 32563150
    [Abstract] [Full Text] [Related]

  • 4. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
    Liu Z, Li Y, Lv C, Wang L, Song H.
    Biochem Biophys Res Commun; 2016 Sep 16; 478(2):893-9. PubMed ID: 27520370
    [Abstract] [Full Text] [Related]

  • 5. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.
    Oncotarget; 2014 Sep 30; 5(18):8637-50. PubMed ID: 25226617
    [Abstract] [Full Text] [Related]

  • 6. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ.
    Leukemia; 2017 Oct 30; 31(10):2065-2074. PubMed ID: 28321124
    [Abstract] [Full Text] [Related]

  • 7. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M, Ai H, Li T, Rajoria P, Shahu P, Li X.
    Biochem Biophys Res Commun; 2016 Apr 15; 472(4):610-6. PubMed ID: 26966074
    [Abstract] [Full Text] [Related]

  • 8. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
    Tan Z, Peng A, Xu J, Ouyang M.
    BMC Anesthesiol; 2017 Sep 29; 17(1):132. PubMed ID: 28962554
    [Abstract] [Full Text] [Related]

  • 9. Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration.
    Xiang W, Cheong JK, Ang SH, Teo B, Xu P, Asari K, Sun WT, Than H, Bunte RM, Virshup DM, Chuah C.
    Oncotarget; 2015 Oct 20; 6(32):33769-80. PubMed ID: 26378050
    [Abstract] [Full Text] [Related]

  • 10. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG, Holyoake TL.
    Biochem Soc Trans; 2007 Nov 20; 35(Pt 5):1347-51. PubMed ID: 17956348
    [Abstract] [Full Text] [Related]

  • 11. Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.
    Riva B, De Dominici M, Gnemmi I, Mariani SA, Minassi A, Minieri V, Salomoni P, Canonico PL, Genazzani AA, Calabretta B, Condorelli F.
    Oncotarget; 2016 Dec 06; 7(49):81555-81570. PubMed ID: 27835591
    [Abstract] [Full Text] [Related]

  • 12. Oxidative lipid damage by naringenin selectively sensitizes chronic myeloid leukemia cell lines and patient samples to Bcr-Abl tyrosine kinase inhibitors.
    Wang M, Deng Q, Zhang W, Qi Q.
    Biochem Biophys Res Commun; 2024 Nov 12; 733():150653. PubMed ID: 39278089
    [Abstract] [Full Text] [Related]

  • 13. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 14. Volatile anesthetics sevoflurane targets leukemia stem/progenitor cells via Wnt/β-catenin inhibition.
    Ruan X, Jiang W, Cheng P, Huang L, Li X, He Y, Mai M, Tan Z.
    Biomed Pharmacother; 2018 Nov 01; 107():1294-1301. PubMed ID: 30257344
    [Abstract] [Full Text] [Related]

  • 15. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S, Tauchi T, Nakajima A, Sashida G, Gotoh A, Broxmeyer HE, Ohyashiki JH, Ohyashiki K.
    Stem Cells Dev; 2007 Jun 01; 16(3):503-14. PubMed ID: 17610380
    [Abstract] [Full Text] [Related]

  • 16. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L, Liu H, Huang J, Xie W, Wei J, Ye X, Qian W.
    Oncotarget; 2017 Jan 31; 8(5):7777-7790. PubMed ID: 27999193
    [Abstract] [Full Text] [Related]

  • 17. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK, Ceylan C, Elmas E, Baran Y.
    Tumour Biol; 2016 Feb 31; 37(2):2365-78. PubMed ID: 26373734
    [Abstract] [Full Text] [Related]

  • 18. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
    Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL.
    Blood; 2008 Mar 01; 111(5):2843-53. PubMed ID: 18156496
    [Abstract] [Full Text] [Related]

  • 19. Local Anesthetic Drug Inhibits Growth and Survival in Chronic Myeloid Leukemia Through Suppressing PI3K/Akt/mTOR.
    Zheng Q, Peng X, Yu H.
    Am J Med Sci; 2018 Mar 01; 355(3):266-273. PubMed ID: 29549929
    [Abstract] [Full Text] [Related]

  • 20. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R.
    Blood; 2013 Mar 07; 121(10):1824-38. PubMed ID: 23299311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.